Bevacizumab, a VEGF-targeting antibody, failed in a clinical trial evaluating the effect of the combination of bevacizumab to radiotherapy-temozolomide (TMZ) for the treatment of newly diagnosed GBM. The gene discussed is VEGFA; the disease is glioblastoma.